Radiant insight Published “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline”
Description
GBI Research’s latest report,
“Innovation and
Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” is a
comprehensive, granular analysis of the 25,522 products currently in the
pharmaceutical industry pipeline, from the Discovery stage through to
Pre-registration and split into therapy areas and key indications. This
pipeline is also benchmarked against its size across each segment compared to
2015 and 2016, and an assessment of the level of first-in-class innovation is
provided. In addition, a detailed contextual analysis of the key drivers of
this pipeline is provided, in addition to an assessment of companies present in
the pipeline and historical deal value and volume.
Innovation,
particularly the development of new products, is a crucial element of the
pharmaceutical industry. The market is highly research-intensive, being deeply
reliant on a high level of R&D investment and a strong product pipeline to
maintain growth and ensure long-term revenue generation. Without successful
innovation, which can be broadly defined as the market launch of novel therapeutic
molecules that cost-effectively treat or cure diseases, the industry would face
a substantial long-term decline in revenue.
A particular focus of
this report is placed on analysis of the development of innovative drugs,
specifically first-in-class innovation. Over recent decades, in addition to an
increase in the yearly number of new chemical entity approvals by the FDA, the
number and proportion of these approvals that were first-in-class at the time
of approval have also increased. The proportion of first-in-class approvals has
increased steadily each year since 1994, with the exception of the years
2005–2008, when the proportion was relatively high.
Scope
- What is the current
size and composition of the pharmaceutical industry pipeline and how has it
changed in the last two years? What can we learn from this?
- The largest therapy
area, by a substantial margin, is oncology, and, with growth in the pipeline
sizes for all major oncology indications since Q1 2015, this trend appears set
to continue. Why is this the case?
- What is the overall
advantage for companies including first-in-class product developments in their
pipeline portfolio, rather than opting for better-characterized established
molecular targets?
- What factors have
been driving the increasing number of first-in-class product approvals over
recent decades?
- Historically, what
has the risk of clinical trial attrition been across each therapy area and
molecule type in the pharmaceutical industry?
- How long have their
associated clinical trials been and how many patients, on average, were
recruited?
Request for Discount- https://www.radiantinsights.com/research/innovation-and-clinical-trial-tracking-factbook-2017/request-sample
Key Reasons to Purchase
- Achieve an
up-to-date understanding of the landscape of the overall pharmaceutical
pipeline, on both a broad and granular level; this also provides a highly
accessible reference which is useful in any pharmaceutical strategic decision
making process
- Benchmark key
therapy areas and indications in terms of the number of pipeline products and
level of innovation, and assess one’s own strategic positioning against this
backdrop
- Understand the
contemporary role and importance of radical and incremental innovation within
the various disease areas and indications
- Make key decisions
about the role of innovation within one’s own pipeline portfolio
- Understand and
benchmark the risk of attrition, clinical trial duration and size across the
pharmaceutical industry
Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 5
2.1 Increasing Cost of
Drug Development 7
2.2 Most Drugs Fail to
Recuperate R&D Costs 8
2.3 Contracting Life
Cycles for Approved Products 9
2.4 The Case for
First-in-Class Pharmaceutical Innovation 10
3 Assessment of the Pharmaceutical Industry
Pipeline 14
3.1 Pipeline and
Clinical Trials Landscape by Therapy Area 14
3.2 Pipeline by Stage
of Development 19
3.3 Pipeline by
Molecule Type 22
3.4 Key Therapy Areas
by Indication 26
3.4.1 Oncology 26
3.4.2 Infectious
Diseases 27
3.4.3 Central Nervous
System 29
3.4.4 Immunology 32
About Us
Radiant Insights is a
platform for companies looking to meet their market research and business
intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
Contact Us
Michelle Thoras
Corporate Sales
Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free:
1-888-202-9519
No comments:
Post a Comment